Intellectual Property & Brand Exclusivity in Lifesciences
Intellectual property assets are of extreme significance in the pharmaceutical and biotechnology sectors, serving both innovators and generic manufacturers. Maintaining a high-value portfolio depends on a company’s resources, R&D investments, and strategic goals. Research-driven enterprises rely heavily on early patenting to recover substantial development costs and secure long-term market exclusivity.
Conversely, generic players require expert design-around strategies, patent landscaping, and early-launch preparations to navigate regulatory exclusivity windows and enter markets smoothly. Incremental innovations, such as novel drug delivery systems or crystalline forms, can be massive game-changers. Notable success stories include the patent licensing of U.S. formulations like Keppra XR from India to European players, and Dynapar AQ formulation triumphs.
Global lifescences IP Expertise
Excelon IP helps biotech and pharmaceutical firms build resilient, highly defensible IP structures. Notably, our founder Sanjaykumar Patel personally managed the global patent prosecution and maintenance for the Keppra XR portfolio during his tenure at Alembic Pharmaceuticals.
Case Study 1: Market-Specific Portfolio Structuring
Landscaping & De-risking Semi-Regulated Market Entry
Industry: Pharmaceutical Research Company
Client Challenge:
The client, an established domestic pharma manufacturer, wanted to expand into semi-regulated global markets. They lacked experience with international IP regulations and needed a market-specific product portfolio tailored to limit patent infringement risks.
Excelon IP Solution:
We conducted a comprehensive product selection analysis. Our team mapped therapeutic segments, analyzed active patents and regulatory exclusivities (with precise expiry timelines), evaluated chemical/formulation development complexities, and quantified market sizes.
Business Impact & Benefit:
Slashed Time-to-Market & Safe Pipeline Setup
The detailed landscape report enabled management to quickly select high-margin, low-risk products. They finalized their product development timeline, designed their R&D pipeline, and allocated budgets with complete legal clarity.
Case Study 2: T-Cell Therapy Patent & Subsidy Acquisition
Biotech Process Patenting & Government Funding
Industry: Biotech Research Company
Client Challenge:
The client developed an innovative method for T-cell therapy process optimization. They wrongly assumed biological processes were ineligible for patent protection and were highly concerned about the capital required for patent filing.
Excelon IP Solution:
Excelon IP clarified the legal thresholds of biotechnology patentability, showing how their specific process features qualified. To resolve their cost constraints, we guided them through the government subsidy scheme application for active IP filings.
Business Impact & Benefit:
Secured Patents & Non-dilutive Funding
The client successfully filed a patent on their core process while receiving substantial government subsidies. Backed by their pending patent status, they secured additional research funding and filed a second patent for a derivative invention.